Participants 52 98 7
 patients with pulmonary arterial hypertension
Participants 172 224 7
n patients with pulmonary arterial hypertension (PAH
Participants 494 581 5
y randomized patients with PAH to receive placebo or sitaxsentan 50 or 100Â mg once dai
Participants 895 964 7
 Of 98 randomized patients, 61% were WHO functional class II at basel
